Semax / NA-Semax / NA-Semax-Amidate Testing
MW: 813.94 g/molHalf-life: Minutes systemically.
Heptapeptide based on the ACTH(4-10) fragment; cognitive research compound.
Mechanism of action
Synthetic heptapeptide based on N-terminal ACTH(4-10), with added Pro-Gly-Pro stabilization. Nootropic and neuroprotective effects via BDNF and NGF expression. Used in Russian neurology since the 1990s for stroke and cognitive disorders.
Sequence & structure
Met-Glu-His-Phe-Pro-Gly-Pro (7 residues) — plus N-acetyl and amidate variants
Three variants like Selank — plain, N-acetyl, and N-acetyl-amidate. Methionine oxidation is the primary stability concern.
Research areas
- ●Stroke recovery (approved in Russia)
- ●ADHD research
- ●Optic nerve and retinal disorders
- ●Cognitive enhancement
What we test on Semax / NA-Semax / NA-Semax-Amidate
RP-HPLC, intact-mass LC-MS, MS/MS sequence, Met oxidation quantitation.
Standard Cognitive / Nootropic Panel
- ✓RP-HPLC purity
- ✓LC-MS/MS identity (modification confirmation)
- ✓Residual solvents
Common impurities & failure modes
- Met1 oxidation
+16 Da; activity loss. Single most common impurity in aged Semax.
- Wrong N-terminal modification
Variant mis-labeling, same as Selank.
- Wrong C-terminus
Free acid vs. amide.
Related Cognitive / Nootropic peptides
Dihexa
456.62 g/mol
Small-molecule angiotensin IV analog; potent neurotrophic compound.
DSIP (Delta Sleep-Inducing Peptide)
848.81 g/mol
Nonapeptide originally isolated from rabbit cerebral venous blood; sleep research.
Noopept
318.37 g/mol
Synthetic dipeptide derivative; widely studied as a nootropic.
P21 Peptide
~2200 g/mol
Synthetic peptide derived from CNTF; neurogenic research compound.
PE 22-28
~830 g/mol
Shortened spadin analog blocking TREK-1 potassium channels; depression research.
Selank / NA-Selank / NA-Selank-Amidate
751.88 g/mol
Heptapeptide based on tuftsin; Russian-developed anxiolytic research peptide. Available as plain, N-acetyl, and amidated variants.